USA flag logo/image

An Official Website of the United States Government

MICRODROPLET BASED SUSTAINED DELIVERY OF NALTREXONE

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
16814
Program Year/Program:
1991 / SBIR
Agency Tracking Number:
16814
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Research Triangle
4364 South Alston Avenue Durham, NC 27713
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1991
Title: MICRODROPLET BASED SUSTAINED DELIVERY OF NALTREXONE
Agency: HHS
Contract: N/A
Award Amount: $46,575.00
 

Abstract:

MICRODROPLET TECHNOLOGY IS A NOVEL MEANS OF IMPROVING TISSUECOMPATIBILITY AND PROVIDING SUSTAINED RELEASE OF A WATER INSOLUBLE DRUG BY DISSOLVING IT INTO MICROSPHERES, (O, LU DIAMETER) OF AN OIL PHASE AND ENCAPSULATING THEM WITHA LAYER OF PHOSPHOLIPID. A RAT MODEL WILL BE USED TO TEST TTHE MICRODROPLET TECHNOLOGY-BASED SUSTAINED DELIVERY OF A NARCOTIC ANTAGONIST, NALTREXONE. NALTREXONE IS THE DRUG OF CHOICE FOR TREATMENT OF HEROIN ADDICTION BECAUSE IT IS ESSENTIALLY A PURE NARCOTIC ANTAGONIST AND DEVOID OF ANALGESIC EFFECTS. A SERIES OF MICRODROPLET FORMATIONS CONTAINING DIFFERENT CONCENTRATIONS OF NALTREXONE WILL BE PREPARED IN AT LEAST THREE TISSUE-COMPATIBLE AND FDA APPROVED SYNTHETIC OILS. THE DRUG RELEASE KINETICS OF THE NALTREXONE-CONTAINING MICRODROPLETS WILL BE TESTED IN A IN VITRO MODEL AS WELL AS BY SUBCUTANEOUS AND INTRAMUSCULAR INJECTIONS INTO RATS. A FORMULATION WHICH PROVIDES ACCEPTABLE (ZERO ORDER) RELEASE KINETICS OVER A PERIOD OF 3-4 WEEKS WILL BE IDENTIFIED FOR FURTHER DEVELOPMENT IN A PHASE II SBIR FOR ITS POTENTIAL INDICATION FOR THE TREATMENT OF HEROIN ADDICTS. MICRODROPLET TECHNOLOGY IS A NOVEL MEANS OF IMPROVING TISSUECOMPATIBILITY AND PROVIDING SUSTAINED RELEASE OF A WATER INSOLUBLE DRUG BY DISSOLVING IT INTO MICROSPHERES, (O, LU DIAMETER) OF AN OIL PHASE AND ENCAPSULATING THEM WITHA LAYER OF PHOSPHOLIPID. A RAT MODEL WILL BE USED TO TEST TTHE MICRODROPLET TECHNOLOGY-BASED SUSTAINED DELIVERY OF A NARCOTIC ANTAGONIST, NALTREXONE. NALTREXONE IS THE DRUG OF CHOICE FOR TREATMENT OF HEROIN ADDICTION BECAUSE IT IS ESSENTIALLY A PURE NARCOTIC ANTAGONIST AND DEVOID OF ANALGESIC EFFECTS. A SERIES OF MICRODROPLET FORMATIONS CONTAINING DIFFERENT CONCENTRATIONS OF NALTREXONE WILL BE PREPARED IN AT LEAST THREE TISSUE-COMPATIBLE AND FDA APPROVED SYNTHETIC OILS. THE DRUG RELEASE KINETICS OF THE NALTREXONE-CONTAINING MICRODROPLETS WILL BE TESTED IN A IN VITRO MODEL AS WELL AS BY SUBCUTANEOUS AND INTRAMUSCULAR INJECTIONS INTO RATS. A FORMULATION WHICH PROVIDES ACCEPTABLE (ZERO ORDER) RELEASE KINETICS OVER A PERIOD OF 3-4 WEEKS WILL BE IDENTIFIED FOR FURTHER DEVELOPMENT IN A PHASE II SBIR FOR ITS POTENTIAL INDICATION FOR THE TREATMENT OF HEROIN ADDICTS.

Principal Investigator:

Indu Parikh
9193612286

Business Contact:

Small Business Information at Submission:

Research Triangle Pharmctcls
4364 S Alston Ave Durham, NC 27713

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No